MBC Pharma, Inc. is a pharmaceutical company discovering and developing novel medicines for the treatment of oncology, bone and infectious diseases. MBC Pharma's patented technologies improve upon the benefit of known drugs by adding tissue targeting and increased cancer cell specificity and uptake.

Hadasit is the technology transfer company of Hadassah Medical Center in Jerusalem. They transform the cutting-edge research coming out of Hadassah into marketable medical technologies. They turn ground-breaking ideas into viable products and services that can change the world and better humanity. For more than a century, Hadassah has set the standard of excellence for medical care and research in Israel. Their doctors and scientists are on the frontlines, uniquely positioned to pinpoint ever-evolving medical needs. Their experience and ingenuity has yielded new ideas with huge potential in all areas of medicine, including therapeutics, diagnostic medical devices, and digital health. More than half of all hospital research in Israel is conducted at Hadassah. Hadasit is Hadassah’s vehicle for commercialization of the intellectual property and R&D capabilities developed there. Hadasit holds exclusive rights to every innovation and invention emerging from Hadassah and they are dedicated to bringing these life-saving technologies to the general public.

BonAlive Biomaterials Oy is a holding company that provides solutions to heal patients with bone defects. It develops synthetic biomaterial solutions for the treatment of chronically infected bone. Their products include BonAlive granules and BonAlive putty, which are osteostimulative; BonAlive granules, which inhibits bacterial growth and act as tool for bone cavity filling in the treatment of chronic osteomyelitis; and BonAlive plates, which have been designed for repair of orbital floor trauma. The company was founded by Fredrik Viktor Ollila on November 13, 2009 and is headquartered in Turku, Finland.

Nanjing Dongshang Biotechnology Co., Ltd., established on 2016-09-30, Business scope includes biological,medical technology development,technical consulting,Technical Services,technology transfer,Technical Training(Does not include training or services related to academic education);3D printing technology development,Sales;production of medicines,Sales;Medical Device Sales;automation equipment,Smart device research and development,Sales;Computer software and hardware technology research and development,Sales;Computer Information Technology Services;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

EBI LLC designs, manufactures and markets medical products. The company is headquartered in Parsippany, NJ.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Shanghai Hi-Tech Bio-Engineering Co., Ltd. is a holding company, which manufactures anti-bacteria biological products. It offers anti-infective products for both personal care and animal care. The company was founded in 1993 and is headquartered in Shanghai, China.

Shanghai Hi-Tech United Biotechnology R&D Co., Ltd., established on 2000-12-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Extraction of marine bioactive substances,purification,Synthesis technology research and development;R&D of industrial enzyme preparations;Research and development of bio-based materials technology;Medical Research and Experimental Development;New material technology promotion service;Manufacturing of bio-based materials;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of bio-based materials;Specialty Chemicals Sales(Free of Hazardous Chemicals);Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:pharmaceutical production;Pharmaceutical commissioned production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

Vicus Therapeutics is an immuno-oncology company. Using a rational data-driven discovery process, Vicus transforms FDA-approved drugs into Precision Medicines to damp tumor promoting inflammation, restore immune surveillance and improve treatment tolerance. Its products are in front of two trends simultaneously occurring in the oncology marketplace: the emergence of Immunotherapy to treat cancer and the transition to Precision Medicines that target the right patients with the right drugs at the right doses as the right times. Vicus lead drug, VT-122, is the 1st multi-pathway neuro-immune modulator for the treatment of cancer. VT-122 is a chrono-formulation of etodolac and propranolol that modulate beta adrenergic receptors 1-2, COX-2 enzyme &TRPA1 channel, and the MAPK, PI3K, PKA, AKT and nociception signaling cascades. VT-122 unique MOA, safety and efficacy profile is supported by over one hundred published animal and human studies of its components and component classes across tumor types. VT-122 recently recently completed a Phase 2 study of advanced liver cancer patients receiving sorafenib and investigator-initiated studies of liver, pancreatic and brain cancers. These studies show VT-122 increased median overall survival 4 to 7 months versus standard of care alone and reduced toxicities with no treatment related SAEs. VT-122 has been granted US FDA Orphan Drug designations for the treatment of pancreatic, liver and brain cancers.

Denka Corp., part of Denka Co., Ltd., is an American company located in New York, NY. The firm manufactures and distributes chemical products.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Hangzhou Mingkangjie Medical Technology Co., Ltd., established on 2021-08-12, Business scope includes licensed projects:Class III medical device business;Production of Class II Medical Devices;Internet Information Service for Medical Devices(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Sales of Class I Medical Devices;Production of Class I Medical Devices;Sales of Class II Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.

Kunshan Boqing Biotechnology Co., Ltd., established on 2006-12-29, The business scope includes the production of veterinary drugs(according to<Veterinary drug production license>Approved scope of operation);disinfection products(Enzyme biochemicals only,amino acids and proteins),medical dressing,food additives,Production of Feed Additives,Sales;cosmetic,hygiene products,Sales of pet food supplies;Biological enzymes,Antimicrobial Peptides,genetically engineered product,Research on gene diagnosis and treatment technology;Technology transfer of the aforementioned R&D achievements,technical consulting,Technical Services.(The law in the aforementioned business items,Administrative regulations stipulate pre-licensing operations,restricted operation,Except for prohibited operations)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Changzhou Dingri Environmental Protection Technology Co., Ltd., established on 2014-11-10, Business scope includes technological development of environmental technology products,Technical Services,technical consulting,technology transfer;Design of environmental protection water treatment process;Design of Environmental Protection Equipment,installation and maintenance;Technical development and technical consultation of energy-saving products;Environmental Impact Assessment;Analysis of environmental protection projects;Environmental testing service;Environmental purification material,Environmental Analysis and Testing Instruments,Chemical Products(In addition to dangerous goods)research and development,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Taoheti Technology (Suzhou) Co., Ltd., established on 2018-11-02, Business scope includes medical devices,R&D of instruments and equipment,production and sales,Biochemical reagent sales(except dangerous goods),Research and Development of Biomaterials,Sales and corresponding technical services,Internet retailing of the above related products,Technology platform construction,Technical Services,Information Technology Consulting Services,Patent agency service,Data Processing and Storage Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)